Lymphoma Clinical Trials in Tennessee

Showing 441-460 of 563 trials

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

NCT00633594

This is a Phase I/II multicenter, open-label, dose-escalation study of rituximab, bortezomib, and lenalidomide in the first-line or second-line treatment of patients with Mantle Cell Lymphoma (MCL).

Mantle Cell Lymphoma

SCRI Development Innovations, LLC39 participantsStarted Jun 2008

Terre Haute, Indiana, United States • Terre Haute, Indiana, United States • Chesterfield, Missouri, United States +4 more locations

COMPLETEDPhase 329 miles

Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer

NCT00053053

RATIONALE: Nutritional supplements may help prevent loss of appetite, weight loss, and fatigue in patients with advanced cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two nutritional supplements in preventing loss of appetite, weight loss, and fatigue in patients who have stage III or stage IV solid tumors.

CachexiaLymphomaLymphoproliferative Disorder+1 more

Radiation Therapy Oncology Group472 participantsStarted Dec 2002

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Mobile, Alabama, United States +247 more locations

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer

Lymphoma Trials in Other Cities

Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma

Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients

Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

Cladribine in Patients With Mantle Cell Lymphoma

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma

Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment

Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma

Other Conditions in Tennessee